12:00 AM
Jul 17, 2000
 |  BC Week In Review  |  Clinical News  |  Regulatory

Reminyl galantamine regulatory update

SHP received European Union marketing approval for its Reminyl acetylcholinesterase inhibitor and nicotinic receptor modulator to treat...

Read the full 81 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >